Related Experiment Video
Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Drug Development
Hyemin Lee1, Elizabeth L Zoeller1, Gregory A Cary2
1Emory University, Atlanta, GA, USA.
Researchers identified key protein interactions involving TICAM1 (TIR domain containing adaptor molecule 1) to target the innate immune response in Alzheimer's disease (AD). Assays were developed to screen for small molecule inhibitors, offering a novel therapeutic approach for AD.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- TICAM1 (TIR domain containing adaptor molecule 1) is implicated in Alzheimer's disease (AD) risk and innate immune response.
- TICAM1 links Toll-like receptors to the type 1 interferon response, a key factor in AD pathogenesis.
- TICAM1 is upregulated in AD brains and presents multiple targets for drug development.
Purpose of the Study:
- To validate TICAM1 protein-protein interactions (PPIs).
- To develop screening strategies for targeting TICAM1 pathway in AD.
- To identify potential small molecule inhibitors for therapeutic intervention.
Main Methods:
- Meta-analysis of existing low and high throughput studies on TICAM1 PPIs.
- Experimental validation of identified TICAM1 interactors using NanoPCA and TR-FRET assays.
- Development of screening assays for monitoring TICAM1 interactions.
Main Results:
- Confirmed several reported TICAM1 PPIs using NanoPCA and TR-FRET assays.
- Identified PPIs of TICAM1 with TBK1, TRAF3, and DHX36 as key intervention targets.
- Established screening assays for small molecule inhibitors targeting the TICAM1 pathway.
Conclusions:
- Targeting TICAM1 PPIs offers a novel strategy for modulating innate immune response in AD.
- Key PPIs and screening assays were identified for early-stage drug development.
- This research contributes to the TREAT-AD Center's efforts in Alzheimer's disease therapeutics.
More Related Videos
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
Related Concept Videos
Preclinical Development: Overview
Clinical Trials: Overview
Drug Discovery: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
In Vitro Drug Release Testing: Overview, Development and Validation
Drug Regulation